Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 8/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 8/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.50 |
| ▸ | FNTA | P49354 | 3/20 | 0.40 |
| ▸ | PGGT1B | P53609 | 3/20 | 0.40 |
| ▸ | FNTB | P49356 | 2/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2929683 | 0.80 | ALDH1A1 (0.46) | — | |
| SCHEMBL2926881 | 0.78 | CYP2D6 (0.40) | CYP19A1 | |
| SCHEMBL570342 | 0.71 | CYP11B1 (1.00) | CYP11B1CYP11B2CYP19A1CYP2A6CYP2B6 | |
| SCHEMBL2925331 | 0.71 | ALDH1A1 (0.44) | — | |
| SCHEMBL2930261 | 0.69 | CYP11B1 (0.76) | CYP11B1CYP11B2CYP19A1CYP2A6CYP2B6 | |
| SCHEMBL2928146 | 0.66 | KDM4E (0.39) | — | |
| SCHEMBL10223314 | 0.66 | CYP11B1 (0.69) | CYP11B1CYP11B2CYP19A1CYP2A6CYP2B6 | |
| SCHEMBL1024261 | 0.65 | CYP11B1 (0.84) | CYP11B1CYP11B2CYP19A1CYP2A6CYP2B6 | |
| SCHEMBL77025 | 0.64 | CYP11B1 (1.00) | CYP11B1CYP11B2CYP19A1CYP2A6CYP2B6 | |
| Oxalic Acid SCHEMBL11534580 | 0.64 | CYP19A1 (0.81) | CYP11B1CYP11B2CYP19A1CYP2A6CYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121616-B1 | NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS | CAMPIANI GIUSEPPE (IT) | 2010-09-15 | — | — | EP | claimed |
| US-20100093726-A1 | NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS | GIUSEPPE CAMPIANI (IT) | 2010-04-15 | — | — | US | claimed |
| EP-2121616-B1 | NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS | CAMPIANI GIUSEPPE (IT) | 2010-09-15 | — | — | EP | disclosed |
| US-20100093726-A1 | NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS | GIUSEPPE CAMPIANI (IT) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093726-A1 | NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS | QTRT1, QTRT2, IL4I1 | CYP11B1 2405/4885CYP11B2 2483/4885CYP19A1 3969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.